Platelet-derived growth factor inhibits bone regeneration induced by osteogenin, a bone morphogenetic protein, in rat craniotomy defects.
Platelet-derived growth factor (PDGF) is a potent moderator of soft tissue repair through induction of the inflammatory phase of repair and subsequent enhanced collagen deposition. We examined the effect of recombinant BB homodimer PDGF (rPDGF-BB) applied to rat craniotomy defects, treated with and without bovine osteogenin (OG), to see if bone regeneration would be stimulated. Implants containing 0, 20, 60, or 200 micrograms rPDGF-BB, reconstituted with insoluble rat collagenous bone matrix containing 0, 30, or 150 micrograms OG, were placed into 8-mm craniotomies. After 11 d, 21 of the 144 rats presented subcutaneous masses superior to the defect sites. The masses, comprised of serosanguinous fluid encapsulated by fibrous connective tissue, were larger and occurred more frequently in rats treated with 200 micrograms rPDGF-BB, and were absent in rats not treated with rPDGF-BB. The masses underwent resorption within 28 d after surgery. OG (2-256 micrograms) caused a dose-dependent increase in radiopacity and a marked regeneration of calcified tissue in a dose-dependent fashion within defect sites. However, OG-induced bone regeneration was inhibited 17-53% in the presence of rPDGF-BB. These results suggest that rPDGF-BB inhibited OG-induced bone regeneration and stimulated a soft tissue repair wound phenotype and response.
Marden
L J
LJ
Department of Physiology, U.S. Army Institute of Dental Research, Walter Reed Army Medical Center, Washington, DC 20307-5300.
Fan
R S
RS
Pierce
G F
GF
Reddi
A H
AH
Hollinger
J O
JO
D000818:Animals; D000077214:Becaplermin; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D001862:Bone Resorption; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D002113:Calcification, Physiologic / Q000187:drug effects; D003399:Craniotomy; D004343:Drug Implants; D006133:Growth Substances / Q000494:pharmacology*; D006398:Hematocele / Q000473:pathology / Q000503:physiopathology; D008297:Male; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage / Q000494:pharmacology*; D011506:Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D051381:Rats; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012038:Regeneration / Q000187:drug effects*; D014945:Wound Healing / Q000187:drug effects
C525759:Bmp3 protein, rat; D055398:Bone Morphogenetic Protein 3; D019485:Bone Morphogenetic Proteins; D004343:Drug Implants; D006133:Growth Substances; D010982:Platelet-Derived Growth Factor; D011506:Proteins; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D000077214:Becaplermin